Background: Oral bisphosphonates (BPs) are the primary agents for the treatment of osteoporosis. Although BPs are generally well tolerated, serious gastrointestinal adverse events have been observed. Aim: To assess the risk of severe upper gastrointestinal complications (UGIC) among BP users by means of a large study based on a network of Italian healthcare utilization databases. Methods: A nested case-control study was carried out by including 110,220 patients aged 45 years or older who, from 2003 until 2005, were treated with oral BPs. Cases were the 862 patients who experienced the outcome (hospitalization for UGIC) until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic regression model was used to estimate odds ratio (OR) associated with current use of BPs after adjusting for several covariates. A set of sensitivity analyses was performed in order to account for sources of systematic uncertainty. Results: The adjusted OR for current use of BPs with respect to past use was 0.94 (95% Cl 0.81 to 1.08). There was no evidence that this risk changed either with BP type and regimen, or concurrent use of other drugs or previous hospitalizations. Conclusions: No evidence was found that current use of BPs increases the risk of severe upper gastrointestinal complications compared to past use.
Risk of Severe Upper Gastrointestinal Complications among Oral Bisphosphonate Users / Arianna, Ghirardi; Lorenza, Scotti; Antonella, Zambon; Gianluca Della, Vedova; Luca Cavalieri, D'Oro; Francesco, Lapi; Francesco, Cipriani; Achille P., Caputi; Alberto, Vaccheri; Dario, Gregori; Rosaria, Gesuita; Vestri, Anna Rita; Tommaso, Staniscia; Giampiero, Mazzaglia; Giovanni, Corrao. - In: PLOS ONE. - ISSN 1932-6203. - 8:12(2013), p. e73159. [10.1371/journal.pone.0073159]
Risk of Severe Upper Gastrointestinal Complications among Oral Bisphosphonate Users
VESTRI, Anna Rita;
2013
Abstract
Background: Oral bisphosphonates (BPs) are the primary agents for the treatment of osteoporosis. Although BPs are generally well tolerated, serious gastrointestinal adverse events have been observed. Aim: To assess the risk of severe upper gastrointestinal complications (UGIC) among BP users by means of a large study based on a network of Italian healthcare utilization databases. Methods: A nested case-control study was carried out by including 110,220 patients aged 45 years or older who, from 2003 until 2005, were treated with oral BPs. Cases were the 862 patients who experienced the outcome (hospitalization for UGIC) until 2007. Up to 20 controls were randomly selected for each case. Conditional logistic regression model was used to estimate odds ratio (OR) associated with current use of BPs after adjusting for several covariates. A set of sensitivity analyses was performed in order to account for sources of systematic uncertainty. Results: The adjusted OR for current use of BPs with respect to past use was 0.94 (95% Cl 0.81 to 1.08). There was no evidence that this risk changed either with BP type and regimen, or concurrent use of other drugs or previous hospitalizations. Conclusions: No evidence was found that current use of BPs increases the risk of severe upper gastrointestinal complications compared to past use.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
